Boehringer Ingelheim applies for clearance to acquire Merial from Sanofi
Published03 Aug 2016
The Commerce Commission has received an application from Boehringer Ingelheim International GmbH seeking clearance to acquire 100% of the shares and assets in Merial, the animal health business of Sanofi SA.
The Commerce Commission has received an application from Boehringer Ingelheim International GmbH seeking clearance to acquire 100% of the shares and assets in Merial, the animal health business of Sanofi SA.
Boehringer Ingelheim and Sanofi are global manufacturers of pharmaceutical and vitamin products for humans and for animals, which they each distribute in New Zealand.
While Boehringer Ingelheim’s clearance application relates only to animal health products, the Commission will also consider whether the proposed global transaction might impact on competition in any other markets in New Zealand.
A public version of the clearance application is available on the Commission’s Clearances Register.
Background
When considering a proposed merger, the Commission must determine whether the competition that would be lost with the merger would be substantial.
We will give clearance to a proposed merger only if we are satisfied that the merger is unlikely to have the effect of substantially lessening competition in a market.
